AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04611451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: Whole body vibration (WBV), which is a new treatment method and applied through the device, is defined as mechanical repetitive motion or oscillatory motion occurring around a balance point
Study NCT04611451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration exercise
Description: Whole body vibration exercise
Study NCT03937492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GMI protocol
Description: This group follow GMI program split in 3 step:~1. left/right descrimination~2. visual motor imagery~3. mirror therapy~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week.
Study NCT03937492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Rehabilitation Protocol
Description: This group follow standard rehabilitation protocol, with active and passive motion of upper limb structure, including hand, wrist, elbow, shoulder.~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week.
Study NCT03937492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitation Protocol
Description: This group follow standard rehabilitation protocol, with active and passive motion of upper limb structure, including hand, wrist, elbow, shoulder.~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week.
Study NCT04119011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: (Lactobacillus acidophilus, lactobacillus casei, lactobacillus lactis) and Bifidobacterium (Bifidobacterium bifidum, bifidobacterium longum, bifidobacterium infantis) lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
Study NCT04119011 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
Study NCT00390208 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab
Description: One 0.5 mg intravitreal Ranibizumab injection
Study NCT02862730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Controller in Dual Hormone Mode
Description: The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
Study NCT02862730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subject's insulin pump
Description: Subject will continue on their subcutaneous delivery of insulin on his/her own insulin pump using their own basal rates and carb ratios for meal boluses, managing their blood sugar as they normally would.
Study NCT02862730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Controller in Single Hormone Mode
Description: The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.
Study NCT02862730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode
Description: The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.
Study NCT03959969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: An educational video on pain management after cesarean section. The educational video was put together by two general obstetrician-gynecologists, two maternal fetal medicine specialists, and a palliative care physician.
Study NCT03959969 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The standard of care discharge instructions for postoperative patients after cesarean section that are provided at the institution.
Study NCT03959969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Prescription given for forty tablets of ibuprofen 600 mg every 6 hours as needed for pain.
Study NCT03959969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Prescription given for forty tablets of ibuprofen 600 mg every 6 hours as needed for pain.
Study NCT03959969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Prescription given for twenty tablets of oxycodone 5 mg every 4 hours as needed for pain.
Study NCT03959969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Prescription given for twenty tablets of oxycodone 5 mg every 4 hours as needed for pain.
Study NCT05467787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message-based psychotherapy (MBP)
Description: Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.
Study NCT05467787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-chat Psychotherapy (VCP)
Description: Video Chat Only (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.
Study NCT01822106 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01822106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02892149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Study NCT02892149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
Study NCT04077944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: maternal serum concentration of trace elements and heavy metals levels
Description: The maternal serum levels of trace elements and heavy metals in both groups were measured using an inductively coupled plasma-mass spectrometry (ICP-MS)
Study NCT04134195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: 2mA stimulation for 20 minutes
Study NCT04587726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girl's room video
Description: Girls Room, a body image mini-series, developed in collaboration with Lena Waithe, Dove and CAR.~Video content was informed by empirical evidence related to body image prevention and intervention. The series consists of five, 3-minute videos.~The videos follow the lives of a 5 best friends, and each video targets a key risk factor for body image:~1. Appearance comparison~2. Body appreciation~3. Body talk~4. Body functionality~5. Appearance teasing \& bullying~6. Appearance focus~The five videos aired on Instagram TV (IGTV) in March 2020.
Study NCT02013167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab is administered as a continuous intravenous infusion (CIV).
Study NCT04587726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control video - Chicken Girls
Description: Chicken Girl's Episode - appearance neutral episode matched for target audience and video length
Study NCT00445146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVG
Description: Elvitegravir (EVG) tablet administered orally once daily with food
Study NCT00445146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: Ritonavir (RTV; /r) 100 mg capsule administered orally once daily with food
Study NCT00445146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV regimen
Description: The components of the ARV regimen will be selected by the investigator without input from the sponsor. The antiretroviral regimen must consist of at least 2 agents, not including the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz, nevirapine, or delavirdine; the protease inhibitors saquinavir, nelfinavir, or indinavir; or investigational agents (without sponsor approval).
Study NCT02013167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Chemotherapy
Description: * FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen (e.g. idarubicin 10 mg/m² days 1 \& 3; fludarabine 30 mg/m² days 1-5; cytarabine arabinoside 2 g/m² days 1-5). Patients > 60 years: Idarubicin 5 mg/m² day 1 \& 3; fludarabine 20 mg/m² day 1-5; cytarabine arabinoside 1 g/m² day 1-5~* HiDAC (high-dose cytarabine arabinoside) - based regimen ≥1 g/m²/day ± anthracycline and/or in combination with other drugs such as native Escherichia coli asparaginase, polyethylene glycol linked to asparaginase (PEG-asparaginase), vinca alkaloids, steroids, etoposide or alkylating agents~* High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours) in combination with native E. coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents.~* Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days.
Study NCT02453958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-modal assessment system
Description: Subjects were assessed using a multi-modal concussion assessment battery incorporating eye-tracking, balance, and neurocognitive tests
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAS41004 IMP3
Description: daily topical application
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS41004 IMP3
Description: daily topical application
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP4
Description: daily topical application
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAS41004 IMP4
Description: daily topical application
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS41004 IMP4
Description: daily topical application
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP6
Description: daily topical application
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAS41004 IMP6
Description: daily topical application
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS41004 IMP6
Description: daily topical application
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP5
Description: once daily, topical
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAS41004 IMP5
Description: once daily, topical
Study NCT02111499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS41004 IMP5
Description: once daily, topical
Study NCT01852175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasugrel 60mg loading dose and 10mg maintenance dose
Study NCT01852175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 180mg loading dose and 90mg bid maintenance dose
Study NCT02035345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01364389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: 3 mg/kg
Study NCT01364389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Description: 3 mg/kg
Study NCT03397082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine gel
Description: 5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade.
Study NCT03397082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mL of sterile gel applied topically to cervix previous to clamping and paracervical blockade.
Study NCT01364389 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: 20 mg
Study NCT01364389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to AIN457, ACZ885 and prednisone
Study NCT01364389 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Matching placebo to AIN457, ACZ885 and prednisone
Study NCT01975597 — intervention group
Intervention type: PROCEDURE
Intervention: Bone marrow aspirates and biopsy
Study NCT02568592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Fat
Description: High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)
Study NCT02568592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal
Description: Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)
Study NCT02568592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal + Extra Fat
Description: Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORMAL, with an additional 30% extra energy coming from fat.
Study NCT03362372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet counseling
Description: The participants of the intervention CAP will enter into an educational program to increase adherence to the DiMet that will integrate three operational components:~1. Explain the particularities of DiMet and the benefits of its monitoring. It will be an individual visit of 25-30 minutes (V1) where the study variables will be collected and the medical tests will be performed and repeated annually for two years (V3 and V5).~2. Clarify the doubts of the DiMet monitoring and the advice received. It will be a telephone visit to reinforce the intervention, with annual frequency, for two years (V2 and V4).~3. Report on DiMet's own foods, cooking habits, adapted recipes and other related topics. It will be for access to an ad hoc designed nutrition blog.
Study NCT03337282 — intervention group
Intervention type: PROCEDURE
Intervention: Protocolized general anesthesia
Description: Induction and maintenance of general anesthesia, post-operative analgesia with protocolized drugs and doses. Maintenance of MAP +/- 20% of baseline with vasopressors as needed.
Study NCT03200899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAPSS-MS
Description: MAPSS-MS is a computer-assisted cognitive rehabilitation intervention. It is a combination of home computer training and 8-weeks of group sessions on lifestyle change and compensatory cognitive strategies.
Study NCT03200899 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care plus computer games
Description: Participants assigned to this arm receive their usual medical care and referral to the My Brain Games website.
Study NCT04457609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir
Description: Current standardized treatment for Covid-19
Study NCT04457609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Current standardized treatment for Covid-19
Study NCT02067962 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Blood sample
Study NCT00980460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT02642380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 cycles)
Description: dexamethasone 40mg daily for 4 consecutive days every 14 days for 4 courses
Study NCT02642380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone (1 cycle)
Description: dexamethasone 40mg daily for 4 consecutive days
Study NCT01019369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone 17-Acetate
Description: Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
Study NCT01019369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone 17-Acetate
Description: Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
Study NCT00753363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: 6 months of weight loss
Study NCT00753363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: 6 months of aerobic exercise training
Study NCT03934853 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dynamic Dental Navigation
Description: Aid in dental implant placement in humans
Study NCT00888342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: supplementary oxygen
Description: Supplementary oxygen 2 L/min if SpO2 \< 90%. If SpO2 \< 90 % the oxygen dose is titrated until SpO2 reads 88-92%. For patients on LTOT the oxygen dose is doubled for intervention.
Study NCT00888342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zopiclone
Description: 5 mg sedative given approximately 1 hour before sleep
Study NCT00888342 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: alcohol
Description: 5 mg alcohol/kg body-weight approximately 1 hour before sleep
Study NCT00392990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen A
Description: Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen
Study NCT00392990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen B
Description: Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)
Study NCT00241904 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Changes
Description: Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise
Study NCT00241904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet Agents
Description: Aspirin 81 mg q day
Study NCT00241904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta Blocker
Description: Oral medication
Study NCT00241904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE Inhibitors
Description: Oral medications, received 1-2 times per day
Study NCT03441230 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon characteristics
Description: Different size balloon
Study NCT01337544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HAPLOIDENTICAL IL-15 STIMULATED NK CELLS
Description: ONE MEGADOSE 30 DAYS AFTER TRANSPLANTATION (DOSE WILL DEPEND ON PATIENT BODY WEIGHT)
Study NCT02422849 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hospital specialist
Study NCT02422849 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: General Practitioner
Study NCT03576911 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Study NCT03576911 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02401984 — intervention group
Intervention type: OTHER
Intervention: Screening
Description: Participants will fill out a short screening questionnaire where different aspects of mental health and behavioral problems will be assessed.